Here's da facts folks....you all know by now I'm a nit-picker (or knit-picker ala Gainsy)
The CombiRx trial, is in phase 3. The first large-scale clinical study evaluating the combination of IM IFN β-1a and glatiramer acetate in RRMS, is currently under way at 80 centers in North America. Approximately 1,000 patients are being randomized to receive the combination (IM IFN β-1a 30 µg once weekly plus SC glatiramer acetate 20 mg once daily) or either agent alone for 36 months. The primary objective is to compare relapse rates in the 3 treatment groups. A previous pilot study of this combination suggested that it was safe and warranted further investigation.
I don't think the CombiRX trial, which began in 2005, would still be cranking along unless some folks were benefitting. I am not anti or pro pharma...no agenda here. As I said in my earlier post, these two medicines affect different aspects of the immune system...using them together adds a one/two punch- myelin-based protein decoy and interferon. The trial is being sponsored by the NIH, and is still recruiting. It means 8 shots a week, one more than just copaxone.